The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Oral Solid Dosage Pharmaceutical Formulation Market Change Between 2026 And 2030?
The oral solid dosage pharmaceutical formulation market size has experienced robust growth in recent years. This market is projected to expand from $653.26 billion in 2025 to $692.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.0%. In the past, this expansion has been driven by several factors, including the broad acceptance of oral drug delivery, a well-established manufacturing infrastructure for tablets and capsules, the increasing prevalence of chronic diseases, the economic efficiency of oral solid dosage forms, and a strong regulatory understanding of oral formulations.
The oral solid dosage pharmaceutical formulation market is anticipated to experience substantial expansion over the upcoming years. Projections indicate it will reach $846.38 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This projected growth can be ascribed to several factors, including the escalating demand for long-acting oral medications, a heightened emphasis on patient adherence and convenience, the expansion of pharmaceutical outsourcing and CDMO services, the global increase in generic drug production, and advancements in excipients and formulation technologies. Key trends anticipated during this forecast duration encompass the increasing adoption of controlled and modified-release dosage forms, a rising preference for patient-friendly oral solid formats, the broadening scope of generic and branded solid dosage manufacturing, a heightened concentration on formulations with high bioavailability, and a move towards cost-optimized and scalable oral dosage production.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
Which Growth Factors Are Strengthening The Oral Solid Dosage Pharmaceutical Formulation Market Landscape?
The escalating incidence of chronic diseases is anticipated to fuel the expansion of the oral solid dosage pharmaceutical formulation market moving forward. These are long-term health conditions that persist for an extended period, typically lasting three months or more. The rise in chronic diseases stems from factors such as aging populations, inactive lifestyles, poor dietary habits, environmental influences, and improved detection and diagnostic methods. Oral solid dosage pharmaceutical formulations are essential for managing chronic diseases and promote adherence to long-term treatments due to their convenience, stability, and precise dosing. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, indicating a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of chronic diseases acts as a driver for the growth of the oral solid dosage pharmaceutical formulation market.
What Key Segment Areas Are Included In The Oral Solid Dosage Pharmaceutical Formulation Market Assessment?
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
Which Trends Are Affecting The Oral Solid Dosage Pharmaceutical Formulation Market Framework?
Leading companies in the Oral Solid Dosage (OSD) pharmaceutical market are concentrating on developing innovative solutions, such as fixed dose combinations, to improve efficacy, patient adherence, and safety. A fixed dose combination (FDC) is a medication comprising two or more active drugs integrated into a single dosage form to streamline treatment and enhance patient compliance. For example, in February 2025, Ono Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, obtained approval from the U.S. Food and Drug Administration (FDA) for Journavex (suzetrigine) 50 mg oral tablets designed to treat moderate to severe acute pain in adults. This treatment operates by selectively inhibiting NaV1.8 sodium channels within the peripheral nervous system, thereby blocking pain signals before they reach the brain and providing effective pain relief without the risk of addiction. Clinical trials indicated significant pain reduction compared to a placebo, alongside a well-tolerated safety profile that included minor side effects like itching and muscle spasms.
Who Are The Businesses Driving Activity In The Oral Solid Dosage Pharmaceutical Formulation Market?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Access The Complete Oral Solid Dosage Pharmaceutical Formulation Market Report:
Which Region Is The Primary Market For The Oral Solid Dosage Pharmaceutical Formulation Market?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oral Solid Dosage Pharmaceutical Formulation Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
Browse Through More Reports Similar to the Global Oral Solid Dosage Pharmaceutical Formulation Market 2026, By The Business Research Company
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Oral Solid Dosage Contract Manufacturing Market Report 2026
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model